Amarin Corporation Announces That Investigators Will Present An Additional Subgroup Analysis From The REDUCE-IT Outcomes Trial In Patients With And Without Coronary Artery Disease History And Mechanistic Data On Eicosapentaenoic Acid At The American...
Amarin Corporation Announces That Investigators Will Present An Additional Subgroup Analysis From The REDUCE-IT Outcomes Trial In Patients With And Without Coronary Artery Disease History And Mechanistic Data On Eicosapentaenoic Acid At The American...
Amarin Corporation Announces That Investigators Will Present An Additional Subgroup Analysis From The REDUCE-IT Outcomes Trial In Patients With And Without Coronary Artery Disease History And Mechanistic Data On Eicosapentaenoic Acid At The American Heart Association's Scientific Sessions
阿玛琳公司宣布，调查人员将在美国心脏协会科学会议上展示来自REDUCE-It结果试验的患有和没有冠状动脉疾病史的患者的额外亚组分析，以及关于二十碳五烯酸（EPA）的机械数据
Amarin Corporation plc (NASDAQ:AMRN) today announced that investigators will present an additional subgroup analysis from the landmark REDUCE-IT outcomes trial in patients with and without coronary artery disease (CAD) history and mechanistic data on eicosapentaenoic acid (EPA) at the American Heart Association's Scientific Sessions, November 16-18, 2024 in Chicago, IL.
美国阿玛琳公司plc（纳斯达克代码：AMRN）今日宣布，调查人员将在2024年11月16日至18日于伊利诺伊州芝加哥举行的美国心脏协会科学会议上展示来自里程碑式REDUCE-It结果试验的患有和没有冠状动脉疾病（CAD）史的患者的额外亚组分析，以及关于二十碳五烯酸（EPA）的机械数据
"The data to be presented at the AHA Scientific Sessions continues to affirm the clinical utility and value of VASCEPA/VAZKEPA (icosapent ethyl), not only in the overall REDUCE-IT trial population, but also across various subgroups analyzed to date," said Steve Ketchum, PhD, Chief Scientific Officer at Amarin. "Data presented at AHA will showcase new evidence from the REDUCE-IT CAD subanalysis, highlighting the benefits of VASCEPA/VAZKEPA in secondary prevention patients, with and without CAD history."
"在AHA科学会议上展示的数据继续证实了VASCEPA/VAZKEPA（20碳乙酯）在整体REDUCE-It试验人群以及迄今为止分析过的各种亚组中的临床效用和价值，"阿玛琳公司首席科学官史蒂夫·凯彻姆博士表示。"在AHA上展示的数据将展示REDUCE-It冠状动脉疾病亚分析的新证据，突出了VASCEPA/VAZKEPA在二级预防患者中的益处，无论是否有冠状动脉疾病史。"
Dr. Ketchum further added, "Additional data to be featured at the AHA Scientific Sessions include research highlighting the mechanistic effects of EPA, particularly its antioxidant effects in endothelial cells and the ability of EPA to impact the oxidation of Lp(a) particles. High Lp(a) concentrations are associated with increased CV event risk, and people with high levels face a 2-4 times greater risk of having an early event. With about 20% of the global population affected, research is crucial for understanding and addressing elevated Lp(a)."
凯彻姆博士进一步补充说，"在AHA科学会议上展示的额外数据包括突出EPA的机械作用的研究，尤其是其在内皮细胞中的抗氧化作用以及EPA影响Lp(a)颗粒的氧化的能力。高Lp(a)浓度与增加的心血管事件风险相关，高水平的人面临早期事件风险增加2-4倍。全球人口约20％受影响，研究对于了解和解决高Lp(a)问题至关重要。"
